VINCRISTINE INJECTION 1MG/ML 1ML

Indications:

Acute leukemia, acute lymphoblastic leukemia in children (for the combined therapy), Hodgkin's disease, non-Hodgkin's malignant lymphomas (lymphocytic, histiocytic, smeshannokletochnye, undifferentiated; nodular or diffuse type), multiple myeloma, Ewing's sarcoma, osteosarcoma, soft tissue sarcoma, rhabdomyosarcoma (in including embryonic), breast cancer, lung cancer (small cell), melanoma, mushroom mycosis, Kaposi's sarcoma, cancer of the renal pelvis and ureters, bladder cancer, Wilms tumor, neuro lastoma, cervical cancer, uterine sarcoma, germ cell tumor of the testis and ovary, uterus horionepitelioma, ependimioma, meningioma, neoplastic etiology pleurisy, malignant genital tumors in girls, idiopathic thrombocytopenic purpura (resistant to corticosteroids, and the ineffectiveness splenectomy).

Contraindications:

- neurodystrophic diseases (for example, a demyelinating form of Charcot-Marie-Tut syndrome); - pregnancy; - lactation period; - hypersensitivity to vinoalkalloidoids.

Mode of application:

In / in the jet (not faster than 1 min) or drip, 1 time per week, diluting the contents of the vial with 0.9% NaCl solution to a concentration not higher than 1 mg / ml. Single dose for adults is 0.4-1.4 mg / sq. m (maximum 2 mg), exchange rate - 10-12 mg / sq. mIn patients with a direct bilirubin concentration above 0.3 mg%, a dose reduction of 2 times is required. Children: 2 mg / sq. once a week, for 4-6 weeks, in children weighing less than 10 kg - 0.05 mg / kg. Intrapleural - 1 mg.

Composition:

Vincristine * (Vincristine *)